-
-
-
-
-
-
-
Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
-
-
-
-
-
-
-
Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones
-
-
-
-
-
-
-
Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results
-
-
-
-
-
-
-
Soligenix Announces Recent Accomplishments And Year-End 2022 Financial Results
-
-
-
-
-
-
-
Soligenix Announces Recent Accomplishments And First Quarter 2022 Financial Results
-
-
-
-
-
-
-
Soligenix, Inc. (SNGX) provides corporate update and guidance
-
-
-
-
-
-
1,160,146 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

